Genelux Corporation

NASDAQ:GNLX

Biotechnology

Healthcare
$2.24 +2.63%

+$0.08 today

Market cap
$107.66M
Beta
0.55
P/E (TTM)
-3.0
EPS (TTM)
-$0.98
52W Low $2.29High $8.54

Volume 0.80M

Average 0.19M

GNLX Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Genelux CorporationNASDAQ: GNLX

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses grows in line with its trailing trend

Q1 FY2026 operating expenses of $8.36M rose 7.0% year over year, in line with the +7.3% change in trailing-twelve-month operating expenses. Sequentially, it fell 9.8% from the prior quarter. Over 3 fiscal years it compounded at +35.5% a year.

Context

  • Operating expenses amounted to 408100.0% of revenue in FY2025, up 23087.5 pp from a year earlier.
  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +7.0% toward the trailing-twelve-month pace of +7.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.36M-9.8% QoQ
Last fiscal yearDec 2025
$32.65M+6.0% YoY
LTMMar 2026
$33.48M+7.3% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.0%——
1 year+6.0%——
3-year CAGR+35.5%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
32.65M USD
Year-over-year change
+6.0%
4-year CAGR
+24.2%

Operating Expenses vs competitors

How GNLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +7.3% is the 5th highest of 10, against a peer median of -14.4%.
  • Operating expenses amounts to 418487.5% of revenue for GNLX, versus a peer median of 7543.6%.
GNLX Competitors
Operating Expenses for GNLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LYELLyell Immunopharma, Inc.LTM Mar 2026$189.56M USD-47.4%-10.9%611487.1%
CLLSCellectis S.A.LTM Mar 2026$101.75M USD+11.1%-1.4%149.4%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$97.24M USD-16.4%+21.3%—
SLNSilence Therapeutics plcLTM Mar 2026$87.2M USD—+16.9%9463.1%
ACIUAC Immune S.A.LTM Mar 2026CHF 68.45M CHF-14.4%-1.1%1849.0%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$66.77M USD+256.3%+44.2%—
CADLCandel Therapeutics, Inc.LTM Mar 2026$56.42M USD+67.9%+11.5%—
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$46.29M USD+25.4%+8.5%—
MREOMereo BioPharma Group plcLTM Mar 2026$37.72M USD-21.8%-10.5%7543.6%
GNLXGenelux CorporationLTM Mar 2026$33.48M USD+7.3%+35.5%418487.5%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$28.32M USD-53.7%-17.4%—
Peer median (excluding GNLX) —-14.4%+3.7%7543.6%

Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue011.07M170K8K8K
Cost of Revenue895K968K1.02M903K574K
Gross Profit(895K)10.1M(848K)(895K)(566K)
Gross Margin—91.3%-498.8%-11187.5%-7075.0%
Research & Development6.32M9.08M12.77M19M19.85M
Selling, General & Admin8.29M5M11.57M12.71M13.37M
Operating Expenses13.72M13.11M23.32M30.8M32.65M
Depreciation & Amortization895K968K1.02M903K574K
EBITDA(13.67M)(1.73M)(26.46M)(28.97M)(31.57M)
EBITDA Margin—-15.6%-15562.9%-362075.0%-394637.5%
Operating Income(14.61M)(3.01M)(24.17M)(31.7M)(33.21M)
Operating Margin—-27.2%-14214.7%-396200.0%-415175.0%
Interest Income00244K1.46M1.07M
Interest Expense1.82M1.41M3.97M00
Other Income / Expenses(1.77M)(1.09M)(4.13M)1.83M1.07M
Income Before Tax(16.38M)(4.11M)(28.3M)(29.87M)(32.15M)
Pre-Tax Margin—-37.1%-16645.3%-373362.5%-401812.5%
Income Tax Expense01.1M000
Net Income(17.8M)(5.21M)(28.3M)(29.87M)(32.15M)
Net Margin—-47.0%-16645.3%-373362.5%-401812.5%
EPS (Basic)(0.69)(0.21)(1.16)(0.95)(0.86)
EPS (Diluted)(0.69)(0.21)(1.16)(0.95)(0.86)
Weighted Avg Shares23.62M24.55M24.43M31.45M37.18M
Weighted Avg Shares (Diluted)23.62M24.55M24.43M31.45M37.18M

Genelux Corporation

NASDAQ:GNLX

Intrinsic Alpha fair value

Locked

Current Price

$2.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.